Related Experiment Video
Updated: Feb 2, 2026

High-Throughput Cardiotoxicity Screening Using Mature Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Monolayers
Published on: March 24, 2023
MicroRNAs in the diagnosis and prevention of drug-induced cardiotoxicity
Mikuláš Skála1,2, Barbora Hanousková3, Lenka Skálová3
1Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, Hradec Králové, Czech Republic.
Abstract:
Drug-induced cardiotoxicity is a serious problem associated with the administration of many drugs. MicroRNAs (miRNAs) have been reported to be affected by drugs and other xenobiotics, and the potential of miRNAs as biomarkers and diagnostic tools has been considered. In recent years, an association of certain miRNAs with the cardiotoxicity of some drugs, namely anthracyclines, bevacizumab, cyclosporine A and isoprenaline, has already been found. This review article summarizes available information about the changes in miRNA levels induced by cardiotoxic drugs. Three aspects are discussed: the altered expression of miRNAs in the heart upon treatment with cardiotoxic drugs, circulating miRNAs as promising early biomarkers of cardiotoxicity, and the potential of miRNAs in the prevention and/or attenuation of drug-induced cardiotoxicity. The targeted changes in the level of certain miRNAs by antagomiRs and miRNA mimics are also described and evaluated. In addition, the cardioprotective mechanism of various natural compounds via their effect on miRNA levels are examined.
Insights
Drug-induced cardiotoxicity can be monitored using microRNAs (miRNAs). This review explores how drug-induced cardiotoxicity affects miRNA levels and their potential as biomarkers and therapeutic targets.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Drug-induced cardiotoxicity poses a significant clinical challenge.
- MicroRNAs (miRNAs) are implicated in cellular responses to xenobiotics.
- Emerging evidence links specific miRNAs to cardiotoxicity from drugs like anthracyclines and cyclosporine A.
Purpose of the Study:
- To review alterations in miRNA expression due to cardiotoxic drugs.
- To evaluate circulating miRNAs as early biomarkers for cardiotoxicity.
- To explore the therapeutic potential of miRNAs in preventing or mitigating drug-induced cardiotoxicity.
Main Methods:
- Literature review of studies investigating miRNA changes in response to cardiotoxic agents.
- Analysis of research on circulating miRNAs as diagnostic markers.
- Examination of therapeutic strategies involving miRNA modulation (antagomiRs, miRNA mimics) and natural compounds.
Main Results:
- Cardiotoxic drugs induce significant changes in cardiac miRNA expression.
- Circulating miRNAs show promise as sensitive biomarkers for early cardiotoxicity detection.
- miRNA-targeted therapies and natural compounds exhibit potential for cardioprotection.
Conclusions:
- MicroRNAs are key players in drug-induced cardiotoxicity.
- Targeting miRNAs offers novel diagnostic and therapeutic avenues.
- Further research into miRNA modulation could lead to improved patient outcomes in cardiotoxicity management.
Related Concept Videos
MicroRNAs
MicroRNAs
Cancer Prevention
Some...
Nursing Diagnosis
The nursing diagnosis focuses on evidence-based...
Prevention of Further Absorption of Poison
Preventive Healthcare Services

